

Medical Coverage Policy | Transcutaneous Electrical Nerve Stimulation (TENS)



EFFECTIVE DATE: 09 | 01 | 2023

POLICY LAST UPDATED: 08 | 31 | 2023

OVERVIEW

Transcutaneous electrical nerve stimulation (TENS) describes the application of electrical stimulation to the surface of the skin at the site of pain. TENS may be applied in a variety of settings (in the patient's home, a physician's office, or in an outpatient clinic).

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

Medicare Advantage Plans

The use of TENS is considered medically necessary for treatment of chronic, intractable pain, acute post-operative pain or low back pain.

The use of TENS for any other condition, including but not limited to the treatment of dementia, management of essential tremor, management of attention deficit hyperactivity disorder, and prevention of migraine headaches, is not covered, as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Commercial Products

The use of TENS is considered medically necessary when filed with a covered indication (see Coding section below).

The use of TENS for any other condition, including but not limited to the treatment of dementia, management of essential tremor, management of attention deficit hyperactivity disorder, and prevention of migraine headaches, is considered not medically necessary, as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Evidence of Coverage or Subscriber Agreement for applicable durable medical equipment benefits/coverage.

BACKGROUND

Transcutaneous electrical nerve stimulation (TENS) has been used to treat chronic intractable pain, postsurgical pain, and pain associated with active or post trauma injury unresponsive to other standard pain therapies. It has been proposed that TENS may provide pain relief through the release of endorphins in addition to potential blockade of local pain pathways. TENS has also been used to treat dementia by altering neurotransmitter activity and increasing brain activity that is thought to reduce neural degeneration and stimulate regenerative processes.

TENS devices consist of an electrical pulse generator, usually battery-operated, connected by wire to 2 or more electrodes, which are applied to the surface of the skin at the site of the pain. Since 1977, a large

number of devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. Marketing clearance via the 510(k) process does not require data on clinical efficacy; as a result, these cleared devices are considered substantially equivalent to predicate devices marketed in interstate commerce before May 1976, the enactment date of the Medical Device Amendments. The cleared devices are also equivalent to devices that have been reclassified and do not require a premarket approval application.

Chronic Pain

For individuals who have chronic pain (eg, musculoskeletal, neuropathic, and mixed pain conditions) who receive TENS, the evidence includes numerous randomized controlled trials (RCTs) and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life (QOL), and medication use. The overall strength of the evidence is weak. The best evidence exists for the treatment of chronic, intractable pain. Available evidence indicates that TENS can improve chronic intractable pain in some patients, and there is support for its use in clinical guidelines by specialty societies. To best direct TENS toward patients who will benefit, a short-term trial of TENS is appropriate, with continuation only in patients who show an initial improvement. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Attention Deficit Hyperactivity Disorder (ADHD)

In 2019, the FDA permitted marketing of the first medical device to treat attention deficit hyperactivity disorder (ADHD) - the Monarch® external Trigeminal Nerve Stimulation (eTNS) System by NeuroSigma. The FDA reviewed the system through the de novo premarket review pathway. This prescription only TENS device is indicated for patients 7 to 12 years of age who are not currently taking prescription ADHD medication. The Monarch eTNS System is intended to be used in the home under the supervision of a caregiver. The device generates a low-level electrical pulse and connects via a wire to a small patch that adheres to a patient's forehead, just above the eyebrow.

For individuals who have attention deficit hyperactivity disorder (ADHD) who receive TENS, the evidence includes one RCT. Relevant outcomes are symptoms, functional outcomes, QOL, and medication use. Results of the RCT concluded that TENS is an effective and safe treatment option for pediatric patients with ADHD. However, the study included a small patient sample and was of short duration. Further studies comparing TENS to standard of care therapy for ADHD are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Migraine Headaches

In 2014, the Cefaly® (STX-Med), which is a TENS device, was granted a de novo 510(k) classification by the FDA for the prophylactic treatment of migraine in patients 18 years of age or older. The Cefaly® Acute and Cefaly® Dual devices were cleared by the FDA through the 510(k) process for the acute treatment of migraine inpatients in 18 years of age or older and for both the acute treatment and prophylaxis of migraines in adults, respectively, in 2017. Other TENS devices cleared by the FDA through the 510(k) process for the prophylactic treatment of migraine in patients include Allive (Nu Eyne Co) and HeadaTerm (EEspress) among others.

For the prevention of migraine headaches, a small RCT reported a greater proportion of patients achieving at least a 50% reduction in migraines with TENS than with sham placebo. The RCT also reported modest reductions in the number of total headache and migraine days. This manufacturer-sponsored trial needs corroboration before conclusions can be made about the efficacy of TENS for preventing migraine headaches.

Essential Tremor

In 2018, the FDA reviewed the Cala ONE™ TENS device (Cala Health) via the de novo pathway and granted approval for the device as an aid in the transient relief of hand tremors following stimulation in the

affected hand of adults with essential tremor. This prescription device is contraindicated for use in patients with an implanted electrical medical device, those that have suspected or diagnosed epilepsy or other seizure disorder, those who are pregnant, and patients with swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions. In October 2020, the FDA granted breakthrough device designation to the Cala Trio™ device for the treatment of action tremors in the hands of adults with Parkinson's disease.

Isaacson et al (2020) evaluated the repeated home use of an FDA-cleared wrist-worn neuromodulation device in the Prospective Study for Symptomatic Relief of Essential Tremor with Cala Therapy (PROSPECT) trial. For each active treatment session, the device electrically stimulated the median and radial nerves for 40 minutes with an alternating burst pattern tuned to the frequency of each patient's tremor. The pre-specified co-primary endpoints were improvements on the clinician-rated Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS) and patient-rated Bain & Findley Activities of Daily Living (BF-ADL) dominant hand scores. Of the 263 enrolled patients, 205 completed the visit 3 follow-up and were included in the primary analysis. Results revealed a significant improvement in TETRAS and BF-ADL from pre- to post-stimulation at each clinic visit ($p < .0001$ for all comparisons). Pre-stimulation tremor levels were improved from Visit 1 to 3 on both TETRAS and BF-ADL ($p < .0001$ for both). Patients rated as "severe" or moderate" improved with both TETRAS (49.3% at baseline to 21% at study exit) and BF-ADL (64.8% at baseline to 23% at study exit) scoring. Tremor power is a calculation of amplitude and frequency. Tremor power decreases with lower amplitude motions and lower frequency motions. Tremor power was also noted to significantly improve with therapy from pre- to post-stimulation ($p < .0001$). No device-related serious adverse events were reported. Non-serious device-related adverse events occurred in 18% of patients (eg, persistent skin irritation, sore/lesion, discomfort, electrical burns, and minor skin irritation). Conclusions were that the repeated in home use of this neuromodulation device over 3 months was effective and safe for patients with essential tremor. Limitations identified were the open-label, single-arm design, the lack of consensus for the definition of clinically meaningful improvement in TETRAS or BF-ADL, as well as the exclusion of 58 patients who exited the study early from the pre-specified primary and secondary endpoint analyses.

For individuals who have essential tremor who receive TENS, the evidence includes a nonrandomized study. Relevant outcomes are symptoms, functional outcomes, QOL, and medication use. Results from the nonrandomized study suggest that TENS therapy is effective and safe for patients with essential tremor. However, the trial was limited by its open-label, single-arm design, lack of defined standards for what constitutes a clinically meaningful improvement in stated end points, and exclusion of patients who exited the study early from the pre-specified primary and secondary endpoint analyses. Further studies comparing TENS to standard of care therapy for essential tremor are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Dementia

TENS has also been used to treat dementia by altering neurotransmitter activity and increasing brain activity that is thought to reduce neural degeneration and stimulate regenerative processes. Input from physician specialty societies and academic medical centers were generally in agreement that TENS is investigational for the management of conditions such as dementia.

Other Conditions

A large number of systematic reviews, most conducted by Cochrane, have assessed the use of transcutaneous electrical nerve stimulation (TENS) in the treatment of a variety of pain conditions, including the topics of osteoarthritis, rheumatoid arthritis, pancreatitis, myofascial trigger points, temporomandibular joint pain, cancer pain, neck pain, acute pain, phantom limb pain, labor pain, and chronic backpain. In 2010, the American Academy of Neurology (AAN) published an evidence-based review of the efficacy of TENS for the treatment of pain in neurologic disorders, including low back pain and diabetic peripheral neuropathy.

For individuals with low back pain and myofascial trigger points, available evidence suggests that TENS is ineffective. Available evidence from systematic reviews are inconclusive for cancer pain, osteoarthritis of the

knee, rheumatoid arthritis, phantom knee pain, chronic neck pain, pain after stroke, and pain after spinal cord injury.

Commercial Products

Acute Pain

For individuals who have acute pain (eg, surgical, musculoskeletal, labor, and mixed pain conditions) who receive TENS, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, QOL, and medication use. Overall, evidence for the use of TENS from high-quality trials remains inconclusive for most indications. A systematic review of TENS for acute and chronic pain found some evidence that TENS reduces pain intensity over and above that seen with placebo and other control groups in patients with acute pain, but small-sized trials contributed to imprecision in magnitude estimates. Systematic reviews have found that TENS may help reduce pain in patients with post-operative pain (post-caesarean and total knee arthroplasty), dysmenorrhea, and pain associated with labor and delivery. For low back pain, systematic reviews have found insufficient evidence to support or refute the use of TENS. Randomized controlled trials have reported mixed results in the efficacy of TENS across various acute pain conditions. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

CODING

Medicare Advantage Plans

The following code(s) are covered:

- E0720** Transcutaneous electrical nerve stimulation (TENS) device, two lead, localized stimulation
- E0730** Transcutaneous electrical nerve stimulation (TENS) device, four or more leads, for multiple nerve stimulation
- E0731** Form-fitting conductive garment for delivery of TENS or NMES (with conductive fibers separated from the patient's skin by layers of fabric)

Commercial Products

The following code(s) are covered when filed with a covered diagnosis from the list below:

- E0720** Transcutaneous electrical nerve stimulation (TENS) device, two lead, localized stimulation
- E0730** Transcutaneous electrical nerve stimulation (TENS) device, four or more leads, for multiple nerve stimulation
- E0731** Form-fitting conductive garment for delivery of TENS or NMES (with conductive fibers separated from the patient's skin by layers of fabric)

Covered ICD-10 diagnosis codes:

G89.21-G89.8
G89.4
G90.50-G90.59
M25.50- M25.579
M54.10- M54.18
M54.2
M54.30-M54.32
M54.40-M54.42
M54.5
M54.6
M54.81, M54.89
M54.9
M79.1
M79.2
R52

Medicare Advantage Plans and Commercial Products

The following code(s) are not covered for Medicare Advantage Plans and not medically necessary for Commercial Products:

- K1016** Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve
- K1017** Monthly supplies for use of device coded at K1016
- K1018** External upper limb tremor stimulator of the peripheral nerves of the wrist
- K1019** Supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist

RELATED POLICIES

Chiropractic Services

PUBLISHED

- Provider Update, July 2023
- Provider Update, April 2022
- Provider Update, April 2021
- Provider Update, April 2020
- Provider Update, January 2019

REFERENCES

1. National Coverage Determination (NCD) for Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Post-Operative Pain (10.2)
2. National Coverage Determination (NCD) for Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Low Back Pain (CLBP) (160.27)
3. National Coverage Determination (NCD) for Transcutaneous Electrical Nerve Stimulators (TENS) (280.13)
4. Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination (LCD) for Transcutaneous Electrical Nerve Stimulators (TENS) (L33802). Accessed April 17, 2023.
5. Food and Drug Administration. De Novo Classification Request for Cefaly Device. 2012; http://www.accessdata.fda.gov/cdrh_docs/reviews/K122566.pdf. Accessed September 20, 2022.
6. Food and Drug Administration. Cefaly Dual Device: K173006. 2017; https://www.accessdata.fda.gov/cdrh_docs/pdf17/K173006.pdf. Accessed September 20, 2022.
7. Food and Drug Administration. Cefaly Acute Device: K171446. 2017; https://www.accessdata.fda.gov/cdrh_docs/pdf17/K171446.pdf. Accessed September 20, 2022.
8. Food and Drug Administration. HeadA Term Device: K172450. 2018; https://www.accessdata.fda.gov/cdrh_docs/pdf17/K172450.pdf. Accessed September 20, 2022.
9. Food and Drug Administration. Allive Device: K192773. 2019; https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192773.pdf. Accessed September 20, 2022.
10. Cala Health news release. Cala Health receives FDA breakthrough device designation for Cala Trio therapy to treat action tremors in Parkinson's disease. <https://calahealth.com/uploads/pd-breakthrough-status.pdf>. Accessed September 20, 2022.
11. FDA news release. FDA permits marketing of first medical device for treatment of ADHD. April 19, 2019. <https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-medical-device-treatment-adhd>. Accessed September 20, 2022.
12. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). TENS or PENS in the treatment of chronic and postoperative pain. TEC Assessments. 1996; Volume 11, Tab 21.
13. Bronfort G, Nilsson N, Haas M, et al. Non-invasive physical treatments for chronic/recurrent headache. *Cochrane Database Syst Rev.* 2004(3):CD001878. PMID 15266458
14. Brosseau L, Judd MG, Marchand S, et al. Transcutaneous electrical nerve stimulation (TENS) for the treatment of rheumatoid arthritis in the hand. *Cochrane Database Syst Rev.* 2003(3):CD004377. PMID 12918009
15. Brosseau LU, Pelland LU, Casimiro LY, et al. Electrical stimulation for the treatment of rheumatoid arthritis. *Cochrane Database Syst Rev.* 2002(2):CD003687. PMID 12076504

16. Cameron M, Lonergan E, Lee H. Transcutaneous electrical nerve stimulation (TENS) for dementia. *Cochrane Database Syst Rev.* 2003(3):CD004032. PMID 12917999
17. Carroll D, Moore RA, McQuay HJ, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic pain. *Cochrane Database Syst Rev.* 2001(3):CD003222. PMID 11687055
18. Dowswell T, Bedwell C, Lavender T, et al. Transcutaneous electrical nerve stimulation (TENS) for pain relief in labour. *Cochrane Database Syst Rev.* 2009(2):CD007214. PMID 19370680
19. Hurlow A, Bennett MI, Robb KA, et al. Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. *Cochrane Database Syst Rev.* 2012;3:CD006276. PMID 22419313
20. Khadilkar A, Milne S, Brosseau L, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic low-back pain. *Cochrane Database Syst Rev.* 2005(3):CD003008. PMID 16034883
21. Khadilkar A, Odebiyi DO, Brosseau L, et al. Transcutaneous electrical nerve stimulation (TENS) versus placebo for chronic low-back pain. *Cochrane Database Syst Rev.* 2008(4):CD003008. PMID 18843638
22. Kroeling P, Gross A, Goldsmith CH, et al. Electrotherapy for neck pain. *Cochrane Database Syst Rev.* 2009(4):CD004251. PMID 19821322
23. Cala Health news release. Cala Health receives FDA breakthrough device designation for Cala Trio therapy to treat action tremors in Parkinson's disease. <https://calahealth.com/uploads/pd-breakthrough-status.pdf>. Accessed September 20, 2022.
24. Isaacson SH, Peckham E, Tse W, et al. Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor. *Tremor Other Hyperkinet Mov (N Y).* Aug 14 2020; 10: 29. PMID32864188
25. Hokenek NM, Erdogan MO, Hokenek UD, et al. Treatment of migraine attacks by transcutaneous selectrical nerve stimulation in emergency department: A randomize controlled trial. *Am J Emerg Med.* Jan 2021; 39: 80-85. PMID 31983598
26. Domingues FS, Gayoso MV, Sikandar S, et al. Analgesic efficacy of a portable, disposable, and self-applied transcutaneous electrical nerve stimulation device during migraine attacks: A real-life randomized controlled trial. *Pain Pract.* Nov 2021; 21(8): 850-858. PMID 34013542.

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

